Neurotrope Announces Cooperative Research and Development Agreement for Bryostatin-1 with the National Cancer Institute

Author's Avatar
Feb 04, 2019
Article's Main Image

Collaboration to Support Clinical Study of Bryostatin-1 in Leukemia and B-cell Lymphoma

Bryostatin-1 Upregulation of CD22 Offers Potential to Enhance CD22 Targeted Therapies, Including CAR-T cell therapy

Company Also Announces Completion of Safety Evaluation of Confirmatory, Phase 2, Placebo-Controlled Trial Evaluating Bryostatin-1 in Moderate to Severe Alzheimer's Disease

PR Newswire